Cargando…

Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment

We aimed to identify the characteristics of immune reconstitution (IR) in patients who recovered from steroid-refractory acute graft-versus-host disease (SR-aGVHD) after basiliximab treatment. A total of 179, 124, 80, and 92 patients were included in the analysis for IR at 3, 6, 9, and 12 months, re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Dao-Xing, Fan, Shuang, Zhang, Xiao-Hui, Xu, Lan-Ping, Wang, Yu, Yan, Chen-Hua, Chen, Huan, Chen, Yu-Hong, Han, Wei, Wang, Feng-Rong, Wang, Jing-Zhi, Pei, Xu-Ying, Chang, Ying-Jun, Liu, Kai-Yan, Huang, Xiao-Jun, Mo, Xiao-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351448/ https://www.ncbi.nlm.nih.gov/pubmed/35936697 http://dx.doi.org/10.3389/fonc.2022.916442

Ejemplares similares

P1292: BASILIXIMAB MAY BE THE POTENTIAL SOLUTION FOR SEVERE LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE: A PROSPECTIVE PILOT STUDY
por: Deng, Dao-Xing, et al.
Publicado: (2023)

Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease
por: Shen, Meng-Zhu, et al.
Publicado: (2021)

Basiliximab/steroids/tacrolimus: Pneumonia with Scedosporium apiospermum and Lomentospora prolificans: case report
Publicado: (2021)

Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial
por: Zhao, Ke, et al.
Publicado: (2022)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
por: Fan, Shuang, et al.
Publicado: (2022)

Treatment and unmet needs in steroid-refractory acute graft-versus-host disease
por: Malard, Florent, et al.
Publicado: (2020)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
por: Wang, Dong, et al.
Publicado: (2021)

Prospective Controlled Protocol for Three Months Steroid Withdrawal with Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients
por: Oh, Chang-Kwon, et al.
Publicado: (2012)

The role of basiliximab in the evolving renal transplantation immunosuppression protocol
por: Salis, Paola, et al.
Publicado: (2008)

A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation
por: Shen, Meng-Zhu, et al.
Publicado: (2022)

Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant
por: Yan, Chen-Hua, et al.
Publicado: (2016)

Reconstitution of full‐thickness skin by microcolumn grafting
por: Tam, Joshua, et al.
Publicado: (2016)

Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long‐term clinical outcomes and health‐related quality of life assessment
por: Yan, Chen‐hua, et al.
Publicado: (2022)

Correction to: Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant
por: Yan, Chen-Hua, et al.
Publicado: (2019)

Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts
por: Zhao, Xiang-Yu, et al.
Publicado: (2015)

Murine Models of Steroid Refractory Graft-versus-Host Disease
por: Toubai, Tomomi, et al.
Publicado: (2018)

Basiliximab impairs regulatory T cell (TREG) function and could affect the short-term graft acceptance in children with heart transplantation
por: López-Abente, Jacobo, et al.
Publicado: (2021)

Improving Cytomegalovirus-Specific T Cell Reconstitution after Haploidentical Stem Cell Transplantation
por: Luo, Xiao-Hua, et al.
Publicado: (2014)

Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab
por: Wang, Ricardo, et al.
Publicado: (2015)

Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets
por: Chang, Ying-Jun, et al.
Publicado: (2015)

Intramesenteric Steroid Treatment for Steroid- Refractory Gastrointestinal Graft Versus Host Disease
por: Bilgin, Aynur Uğur, et al.
Publicado: (2012)

Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study
por: Qi, Xiaofei, et al.
Publicado: (2018)

Basiliximab for the therapy of acute T cell–mediated rejection in kidney transplant recipient with BK virus infection: A case report
por: Chen, Tingting, et al.
Publicado: (2022)

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
por: Sageshima, Junichiro, et al.
Publicado: (2009)

Efficacy of basiliximab induction in poorly matched living donor renal transplantation
por: Gundlapalli, S., et al.
Publicado: (2013)

A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation
por: Shen, Meng-Zhu, et al.
Publicado: (2022)

Basiliximab for early perioperative transplant-associated thrombotic microangiopathy after lung transplantation: a case report
por: Ijiri, Naohiro, et al.
Publicado: (2022)

Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation
por: Shen, Meng-Zhu, et al.
Publicado: (2022)

Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial
por: Wang, Yu, et al.
Publicado: (2022)

Basiliximab Induction with Delayed Calcineurin Inhibitors for High-Risk Lung Transplant Candidates
por: Kim, Ha Eun, et al.
Publicado: (2021)

Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study
por: Lam, Ngan N., et al.
Publicado: (2021)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Immune Reconstitution and Graft-Versus-Host Reactions in Rat Models of Allogeneic Hematopoietic Cell Transplantation
por: Zinöcker, Severin, et al.
Publicado: (2012)

Pre‐transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors
por: Sun, Yu‐Qian, et al.
Publicado: (2021)

The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation
por: Zuo, Wei, et al.
Publicado: (2022)

Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease
por: Abedin, Sameem, et al.
Publicado: (2020)

Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience
por: Furukawa, Masashi, et al.
Publicado: (2022)

Corneal perforation associated with ocular graft-versus-host disease
por: Xu, Yue, et al.
Publicado: (2022)

Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis
por: Chang, Ying-Jun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4i6ef5iblf6rva52orsi9mkl0e